Antev

Executive Summary

Antev is a clinical-stage biotechnology company based in London, UK, focused on developing Teverelix, a first-in-market therapy for high cardiovascular risk prostate cancer patients and patients experiencing their first episode of acute urinary retention (AUR) due to benign prostatic hyperplasia. Founded in 2021, the company aims to address significant unmet needs in urological oncology and benign prostatic disease. Teverelix is positioned as a potential alternative to current treatments, with a focus on reducing cardiovascular risks associated with androgen deprivation therapy in prostate cancer and providing a non-surgical option for AUR. The company is currently in Phase 1 clinical development, having advanced its lead candidate into early human trials. Antev's approach leverages a differentiated mechanism of action, targeting GnRH receptors to achieve medical castration while potentially mitigating adverse cardiovascular events. The initial clinical data, if positive, could support progression to Phase 2 trials and attract partnership interest. However, as a private, early-stage entity, the company faces typical execution risks including trial enrollment, funding, and regulatory hurdles.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and tolerability data readout for Teverelix40% success
• Q2 2027Initiation of Phase 2 trial in high CV risk prostate cancer patients30% success
• Q3 2026Regulatory interaction or IND clearance for AUR indication50% success